Drug intelligence / Profile preview

177Lu-anti-CD19 antibody

Development stage
Preclinical
Lead developer
Changping Laboratory
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

177Lu-anti-CD19 antibody is a preclinical-stage therapeutic radiopharmaceutical consisting of a monoclonal antibody targeting B-lymphocyte antigen CD19 conjugated to the beta-emitting radioisotope lutetium-177 (177Lu). Developed by researchers at Changping Laboratory and Peking University, the agent is designed to achieve 'immune resetting' in autoimmune diseases such as systemic lupus erythematosus (SLE). By binding to CD19-expressing B cells and plasma cells, the radiopharmaceutical delivers localized cytotoxic radiation, leading to profound and sustained B-cell depletion and a subsequent reduction in pathogenic autoantibody levels. In preclinical mouse models of SLE, a single dose of 177Lu-anti-CD19 antibody significantly extended survival, improved skin lesions and lupus nephritis, and demonstrated therapeutic efficacy.

Other names
177Lu-CD19 antibody177Lu-anti-CD19
02

Identity

Drug type
Antibody-Based Therapeutics
Modality
Monoclonal AntibodiesAntibody-Radionuclide ConjugatesBeta-minus EmittersGamma Emitters
03

Pharmacology

Route
Intravenous
04

Development

IndicationHighest phaseStatus
systemic lupus erythematosus-associated nephritis (lupus nephritis)PreclinicalActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

  • Changping LaboratoryLead developer
07

Patents & exclusivity

Patents
1

Patent families, expiry dates and exclusivities are in the full profile.

08

Competitive landscape

Drugs on the same target
521
Drugs in the lead indication
163

Lead indication: systemic lupus erythematosus-associated nephritis (lupus nephritis)

Beyond the preview

Go deeper on 177Lu-anti-CD19 antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 177Lu-anti-CD19 antibody.

Work on 177Lu-anti-CD19 antibody? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call